Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
Authors
Javier Cortés
Ramon y Cajal University Hospital, Madrid, Spain
Javier Cortés, Zifang Guo, Vassiliki Karantza, Gursel Aktan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02819518
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS18)
DOI
10.1200/JCO.2018.36.5_suppl.TPS18
Abstract #
TPS18
Poster Bd #
M6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
First Author: Rebecca Dent
Poster
2022 ASCO Annual Meeting
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
First Author: Hope S. Rugo
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).
First Author: Shom Goel
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino